- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07831863
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
A Phase III, Open-label, Randomized-controlled, Multi-center Study of 7MW3711 Compared With Docetaxel in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy and Immunotherapy
To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .
연구 개요
상세 설명
A Phase III, Open-label, Randomized-controlled, Multi-center Study to Evaluate the Safety and Efficacy of 7MW3711 Compared with Docetaxel in Patients with Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy and Immunotherapy.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Shun Lu, Doctor
- 전화번호: 3121 021-22200000
- 이메일: shun_lu@hotmail.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200043
- Shanghai Chest Hospital
-
연락하다:
- Shun Lu, Doctor
- 전화번호: 3121 021-22200000
- 이메일: shun_lu@hotmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- All trial participants or their legally acceptable representatives must sign the Ethics Committee-approved informed consent form before any screening procedures are initiated.
- Aged 18 to 85 years (inclusive) at the time of signing the informed consent, regardless of gender.
- ECOG performance status of 0 to 1.
- Histologically or cytologically confirmed unresectable locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). Mixed pathology including small cell lung cancer or other pathological components must be excluded.
- Must have received prior first-line systemic anti-tumor therapy, including: a) platinum-based doublet chemotherapy; b) immunotherapy (including but not limited to monoclonal antibodies targeting PD-1, PD-L1, CTLA-4, or their bispecific antibodies).
- Radiologically confirmed disease progression during or within 6 months after discontinuation of the most recent treatment regimen.
- Archived tumor tissue samples must be provided.
- Expected survival of ≥ 3 months.
- At least one measurable lesion per RECIST v1.1 criteria at screening. For those with a clear history of radiotherapy, measurable lesions must be outside the radiation field or have shown clear progression after completion of radiotherapy.
- Organ function of trial participants must meet certain criteria.
- Subjects with reproductive potential must take effective contraceptive measures during the trial and for 180 days after the last dose. Female subjects must be confirmed non-pregnant before enrollment, and lactating females must stop breastfeeding, unless surgically sterilized, postmenopausal, or without reproductive potential.
- Able to understand and comply with planned visits, treatment, laboratory tests, and other study procedures.
Exclusion Criteria:
- Received radiotherapy, chemotherapy, or other anti-tumor treatments within 21 days before the first dose; received anti-tumor traditional Chinese medicine within 7 days; received other investigational drugs or devices not yet on the market within 28 days; previously received antibody-drug conjugates (ADCs) or docetaxel.
- Positive for clinically significant driver gene mutations, including EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, HER2.
- Persistent clinically significant toxicities of Grade ≥ 2 related to prior therapy (excluding alopecia and Grade 2 immune-related endocrine toxicities requiring stable doses of replacement therapy).
- Trial participants with clinically symptomatic effusions requiring local therapy or repeated drainage (pleural effusion, ascites, pericardial effusion, etc.).
- Underwent major surgery within 28 days before the first dose of study drug, excluding minor surgeries judged by the investigator as not affecting participation in the trial.
- Received live vaccines within 28 days before the first dose of study drug, or plan to receive any live vaccines during the study period.
- Clinically significant cardiovascular or cerebrovascular diseases within 6 months before the first study drug administration, including but not limited to: acute myocardial infarction, unstable angina, cerebrovascular accident, clinically significant ventricular arrhythmia, NYHA Class III/IV heart failure, QTcF ≥ 470 ms (female) / 450 ms (male), history of long QT syndrome, LVEF < 50% or severe wall motion abnormality, uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg), or other unsuitable arrhythmias.
- History of pulmonary disease requiring steroid therapy; active pulmonary tuberculosis within 1 year before the first study drug administration; pulmonary embolism, severe asthma, or severe chronic obstructive pulmonary disease within 3 months; autoimmune or inflammatory diseases involving the lungs; history of prior pneumonectomy on one side.
- History of gastrointestinal perforation or fistula within 6 months before the first study drug administration, or active gastric/duodenal ulcer, ulcerative colitis, or other gastrointestinal diseases that the investigator considers may cause bleeding or perforation.
- Uncontrolled active bleeding or known bleeding tendency. If imaging shows tumor invasion of major blood vessels or unclear boundaries, or if the investigator judges that the tumor is highly likely to invade important blood vessels during the subsequent study period causing fatal massive bleeding.
- History of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolic event within 3 months before the first study drug administration; portal vein tumor thrombus involving both the main trunk and bilateral first-order branches, or involving both the main trunk and superior mesenteric vein, or inferior vena cava tumor thrombus.
- Presence of any of the following infections: ① Hepatitis B virus; ② Hepatitis C virus; ③ Human immunodeficiency virus; ④ Active Mycobacterium tuberculosis infection; ⑤ Other active infections requiring systemic intravenous anti-infective treatment occurring within 14 days before the first study drug administration; ⑥ Active syphilis infection.
- Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects who have received treatment for brain metastases or have small, asymptomatic, incidental, untreated lesions may be considered for participation, provided that clinical symptoms are stable for at least 4 weeks before study drug administration, no disease progression is confirmed by imaging within 4 weeks before the first dose, all neurological symptoms have completely resolved, no evidence of new or enlarged brain metastases, and radiation, surgery, or steroid therapy was discontinued at least 28 days before the first dose of study treatment. Carcinomatous meningitis and meningeal compression should be excluded regardless of clinical stability.
- Other malignancies within 3 years before the first dose of study drug, except for cured cancers.
- Active autoimmune diseases within 6 months before the first dose of study drug. Subjects with hypothyroidism requiring only stable doses of replacement therapy or skin diseases not requiring systemic treatment are eligible.
- Use of systemic immunosuppressive agents within 2 weeks before the first dose of study drug, excluding: topical glucocorticoids, physiological doses of systemic glucocorticoids, or glucocorticoids used as prophylaxis for hypersensitivity reactions.
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- History of drug abuse or psychiatric illness, or suspected allergy or intolerance to the study drug or any of its components.
- Other conditions judged by the investigator as unsuitable for participation in the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 7MW3711
Participants will receive intravenous (IV) infusion of 7MW3711 as per protocol |
Participants will receive intravenous (IV) infusion of 7MW3711 as per protocol |
|
활성 비교기: Docetaxel
Participants will receive intravenous (IV) infusion of Docetaxel as per protocol |
Participants will receive intravenous (IV) infusion of Docetaxel as per protocol |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival
기간: Up to 34 months
|
Time from the date of randomization until the date of death from any cause. |
Up to 34 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate per investigator
기간: Up to 34 months
|
The percentage of subjects who experience a best response of either CR or PR. |
Up to 34 months
|
|
Progression Free Survival per investigator
기간: Up to 34 months
|
Time from the date of first randomization to the earliest date of documented disease progression per radiological evidence or death from any cause. |
Up to 34 months
|
|
Duration of Response per investigator
기간: Up to 34 months
|
Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause. |
Up to 34 months
|
|
Disease Control Rate per investigator
기간: Up to 34 months
|
The percentage of subjects who experience a best response of CR, PR or stable disease (SD). |
Up to 34 months
|
|
Time to response per investigator
기간: Up to 34 months
|
Time from the date of randomization to the date of CR or PR. |
Up to 34 months
|
|
Incidence of adverse events
기간: Up to 34 months
|
Adverse events will be assessed by investigator(s) according to NCI-CTCAE v6.0 |
Up to 34 months
|
|
SAE(Serious adverse event)
기간: Up to 34 months
|
Adverse events will be assessed by investigator(s) according to NCI-CTCAE v6.0 |
Up to 34 months
|
|
Immunogenicity of 7MW3711
기간: Up to 34 months
|
Incidence of anti-7MW3711 anti-drug antibodies (ADAs) and/or neutralizing antibodies (NAbs) |
Up to 34 months
|
|
Quality of life (QoL) assessed by EORTC QLQ-C30
기간: Up to 34 months
|
Quality of life (QoL) assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 consists of functional scales, symptom scales, and a global health status scale. All scores are linearly transformed to a 0 to 100 scale. For functional scales and global health status, higher scores indicate a better outcome (better functioning/quality of life). For symptom scales, higher scores indicate a worse outcome (more severe symptoms). |
Up to 34 months
|
|
Quality of life (QoL) assessed by EQ-5D-5L
기간: Up to 34 months
|
Quality of life (QoL) assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L consists of a descriptive system (which can be converted into a utility index score) and a visual analogue scale (EQ VAS). The utility index score typically ranges from 0 to 1, where 1 represents full health, 0 represents death, and higher scores indicate a better outcome. The EQ VAS ranges from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state; higher scores indicate a better outcome. |
Up to 34 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 7MW3711-CP301
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .